{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:34:26Z","timestamp":1782930866297,"version":"3.54.5"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["ZIA-AA000218"],"award-info":[{"award-number":["ZIA-AA000218"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience & Biobehavioral Reviews"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.neubiorev.2020.12.030","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T19:13:40Z","timestamp":1610651620000},"page":"296-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"125","author":[{"given":"Roberta","family":"Agabio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Amaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Leggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1905-2025","authenticated-orcid":false,"given":"Julia M.A.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neubiorev.2020.12.030_bib0005","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2174\/138161210791516440","article-title":"Safety and efficacy of baclofen in the treatment of alcohol-dependent patients","volume":"16","author":"Addolorato","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0010","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/alcalc\/37.5.504","article-title":"Baclofen efficacy in reducing alcohol craving and intake: a preliminary double- blind randomized controlled study","volume":"37","author":"Addolorato","year":"2002","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00213-004-2014-4","article-title":"Tolerance to baclofen\u2019s sedative effect in alcohol-addicted patients: no dissipation after a period of abstinence","volume":"178","author":"Addolorato","year":"2005","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2005.08.042","article-title":"Baclofen in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus diazepam","volume":"119","author":"Addolorato","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0025","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.alcohol.2009.09.031","article-title":"Role of the GABA(B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives","volume":"43","author":"Addolorato","year":"2009","journal-title":"Alcohol"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0030","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fnins.2014.00140","article-title":"GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence","volume":"8","author":"Agabio","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0035","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3389\/fpsyt.2018.00464","article-title":"Baclofen in the treatment of patients with alcohol use disorder and other mental health disorders","volume":"9","author":"Agabio","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0040","first-page":"287","article-title":"Targeting the GABAB receptor for the treatment of alcohol use disorder","volume":"15","author":"Agabio","year":"2016"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0045","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2215-0366(18)30303-1","article-title":"Baclofen for the treatment of alcohol use disorder: the Cagliari statement","volume":"5","author":"Agabio","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-4-38","article-title":"GRADE Working Group. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches the GRADE Working Group","volume":"4","author":"Atkins","year":"2004","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0055","series-title":"Effects of Baclofen on Anxiety in Patients with Alcohol Use Disorder (AUD): a Systematic Review and Meta-analysis","author":"Baldwin","year":"2019"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1043-6618(02)00147-0","article-title":"Baclofen analgesia: involvement of the GABAergic system","volume":"46","author":"Balerio","year":"2002","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0065","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.janxdis.2014.06.002","article-title":"Beyond generalized anxiety disorder: psychometric properties of the GAD-7 in a heterogeneous psychiatric sample","volume":"28","author":"Beard","year":"2014","journal-title":"J. Anxiety Disord."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0070","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.euroneuro.2016.10.006","article-title":"Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial","volume":"26","author":"Beraha","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0075","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1037\/tra0000185","article-title":"Posttraumatic stress disorder and alcohol dependence: epidemiology and order of onset","volume":"9","author":"Berenz","year":"2017","journal-title":"Psychol. Trauma"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0080","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s00213-003-1769-3","article-title":"GABA(B) receptor agonists reduce operant ethanol self-administration and enhance ethanol sedation in C57BL\/6J mice","volume":"174","author":"Besheer","year":"2004","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0085","first-page":"337","article-title":"Baclofen: therapeutic use and potential of the prototypic GABAB receptor agonist","volume":"17","author":"Bowery","year":"2016"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0090","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pharmthera.2010.09.007","article-title":"Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse","volume":"129","author":"Breese","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0095","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/acps.12905","article-title":"Baclofen for alcohol use disorder-a systematic meta-analysis","volume":"138","author":"Bschor","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0100","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3389\/fpsyt.2018.00506","article-title":"A review of the potential mechanisms of action of baclofen in alcohol use disorder","volume":"9","author":"de Beaurepaire","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0105","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3389\/fpsyt.2018.00708","article-title":"The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective","volume":"9","author":"de Beaurepaire","year":"2019","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0110","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00127-014-0855-7","article-title":"A systematic review of the comorbidity between PTSD and alcohol misuse","volume":"49","author":"Debell","year":"2014","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0115","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1017\/S0033291700048017","article-title":"The brief symptom inventory: an introductory report","volume":"13","author":"Derogatis","year":"1983","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0120","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3389\/fpsyt.2018.00664","article-title":"Using baclofen to explore GABA-B receptor function in alcohol dependence: insights from pharmacokinetic and pharmacodynamic measures","volume":"9","author":"Durant","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0125","first-page":"197","article-title":"Targeting the GABAB receptor for the treatment of pain","volume":"11","author":"Enna","year":"2016"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0130","doi-asserted-by":"crossref","first-page":"e1108","DOI":"10.1038\/tp.2017.71","article-title":"Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study","volume":"7","author":"Farokhnia","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0135","unstructured":"FDA, February 2015 https:\/\/www.fda.gov\/media\/91222\/download."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0140","first-page":"219","article-title":"Targeting the GABAB receptor for the treatment of depression and anxiety disorders","volume":"12","author":"Felice","year":"2016"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0145","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","article-title":"Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial","volume":"34","author":"Garbutt","year":"2010","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0150","first-page":"1849","volume":"34","author":"Garbutt","year":"2010"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0155","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bj.2015.09.002","article-title":"A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome","volume":"39","author":"Girish","year":"2016","journal-title":"Biomed. J."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0160","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/apt.13965","article-title":"Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore","volume":"45","author":"Goh","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0165","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/08897077.2012.663326","article-title":"Is baclofen a revolutionary medication in alcohol addiction management? Review and recent updates","volume":"33","author":"Gorsane","year":"2012","journal-title":"Subst. Abus."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0170","first-page":"60","article-title":"Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome","volume":"61","author":"Gulati","year":"2019","journal-title":"Indian J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0175","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/00952990.2016.1240797","article-title":"Randomized open-label trial of baclofen for relapse prevention in alcohol dependence","volume":"43","author":"Gupta","year":"2017","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0180","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence--publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0185","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40263-014-0149-3","article-title":"Pharmacological approaches to reducing craving in patients with alcohol use disorders","volume":"28","author":"Haass-Koffler","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0190","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0195","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00127-015-1088-0","article-title":"The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: review and summary of findings","volume":"50","author":"Hasin","year":"2015","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0200","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/add.13787","article-title":"The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial","volume":"112","author":"Hauser","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0205","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.pharmthera.2006.02.001","article-title":"Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms","volume":"111","author":"Heilig","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0210","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2011","journal-title":"Version 5.1.0"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0215","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.drugalcdep.2008.08.010","article-title":"Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome","volume":"99","author":"Howland","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0220","first-page":"CD007505","article-title":"Pharmacotherapy for anxiety and comorbid alcohol use disorders","volume":"1","author":"Ipser","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0225","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.biopsych.2018.02.006","article-title":"The gamma-aminobutyric acid b receptor in depression and reward","volume":"83","author":"Jacobson","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0230","doi-asserted-by":"crossref","first-page":"S467","DOI":"10.1002\/acr.20561","article-title":"Measures of anxiety: state-trait anxiety inventory (STAI), Beck anxiety inventory (BAI), and hospital anxiety and depression scale-anxiety (HADS-A)","volume":"63","author":"Julian","year":"2011","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0235","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/da.20262","article-title":"Role of GABA in anxiety and depression","volume":"24","author":"Kalueff","year":"2007","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0240","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00023210-200923050-00001","article-title":"Complete suppression of craving in alcohol-dependent individuals: Is it possible?","volume":"23","author":"Kiefer","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0245","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.2044-8260.1983.tb00610.x","article-title":"Some norms and reliability data for the State--Trait Anxiety Inventory and the Zung Self-Rating Depression scale","volume":"22","author":"Knight","year":"1983","journal-title":"Br. J. Clin. Psychol."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0250","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0376-8716(93)90057-W","article-title":"Baclofen administration for the treatment of affective disorders in alcoholic patients","volume":"33","author":"Krupitsky","year":"1993","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0255","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11055-016-0379-6","article-title":"Ef\ufb01cacy and safety of the use of baclofen in the treatment of alcohol dependent (a double-blind, randomized, placebo-controlled pilot study)","volume":"47","author":"Krupitsky","year":"2017","journal-title":"Neurosci. Behav. Physiol."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0260","doi-asserted-by":"crossref","first-page":"245","DOI":"10.31887\/DCNS.2015.17.3\/dkupfer","article-title":"Anxiety and DSM-5","volume":"17","author":"Kupfer","year":"2015","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0265","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/alcalc\/agp026","article-title":"Understanding and treating alcohol craving and dependence: recent pharmacological and neuroendocrinological findings","volume":"44","author":"Leggio","year":"2009","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0270","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/187152710790966614","article-title":"Effectiveness and safety of baclofen in the treatment of alcohol dependent patients","volume":"9","author":"Leggio","year":"2010","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0275","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.pbb.2012.11.013","article-title":"A human laboratory pilot study with baclofen in alcoholic individuals","volume":"103","author":"Leggio","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0280","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/070674371205700603","article-title":"Pharmacotherapy of alcohol use disorders and concurrent psychiatric disorders: a review","volume":"57","author":"Lev-Ran","year":"2012","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0285","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0269881112444324","article-title":"British Association for Psychopharmacology, Expert Reviewers Group. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP","volume":"26","author":"Lingford-Hughes","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0290","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000321070","article-title":"Obsessive-compulsive spectrum disorders in obsessive-compulsive disorder and other anxiety disorders","volume":"43","author":"Lochner","year":"2010","journal-title":"Psychopathology"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0295","series-title":"Manual for the Depression Anxiety Stress Scales","author":"Lovibond","year":"1995"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0300","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/jhm.928","article-title":"Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial","volume":"6","author":"Lyon","year":"2011","journal-title":"J. Hosp. Med."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0305","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000481348","article-title":"Reduced drinking in alcohol dependence treatment, what is the evidence?","volume":"23","author":"Mann","year":"2017","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0310","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drugalcdep.2015.03.032","article-title":"Change in psychiatric symptomatology after benfotiamine treatment in males is related to lifetime alcoholism severity","volume":"152","author":"Manzardo","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0315","series-title":"Measuring Health: A Guide to Rating Scales and Questionnaires","author":"McDowell","year":"2006"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0320","first-page":"CD012557","article-title":"Baclofen for alcohol use disorder","volume":"11","author":"Minozzi","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0325","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/alcalc\/agu062","article-title":"Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety","volume":"49","author":"Morley","year":"2014","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0330","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.2018.13","article-title":"Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial","volume":"212","author":"Morley","year":"2018","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0335","first-page":"1167","article-title":"High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial","volume":"25","author":"M\u00fcller","year":"2015","journal-title":"Eur. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0340","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/11597320-000000000-00000","article-title":"Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence","volume":"26","author":"Muzyk","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0345","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jpsychires.2018.09.008","article-title":"Comorbid social anxiety disorder in patients with alcohol use disorder: a systematic review","volume":"106","author":"Oliveira","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0350","doi-asserted-by":"crossref","DOI":"10.1080\/15504263.2013.835164","article-title":"Comorbid alcohol dependence and anxiety disorders: a national survey","volume":"9","author":"Pacek","year":"2013","journal-title":"J. Dual Diagn."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0355","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.euroneuro.2018.03.017","article-title":"Tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis","volume":"28","author":"Pierce","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0360","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/1362361320910963","article-title":"Systematic review of risk and protective factors associated with substance use and abuse in individuals with autism spectrum disorders","volume":"24","author":"Ressel","year":"2020","journal-title":"Autism"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0365","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/alcalc\/agx030","article-title":"A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients-The ALPADIR Study","volume":"52","author":"Reynaud","year":"2017","journal-title":"Alcohol Alcohol."},{"issue":"7","key":"10.1016\/j.neubiorev.2020.12.030_bib0370","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/add.14927","article-title":"Titrated baclofen for high-risk alcohol consumption: a randomized placebo-controlled trial in out-patients with 1-year follow-up","volume":"115","author":"Rigal","year":"2020","journal-title":"Addiction"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0375","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/add.14191","article-title":"Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis","volume":"113","author":"Rose","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0380","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/da.22433","article-title":"Influence of study design on treatment response in anxiety disorder clinical trials","volume":"32","author":"Rutherford","year":"2015","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0385","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s10862-016-9571-9","article-title":"Psychometric properties of the generalized anxiety disorder scale-7 (GAD-7) in outpatients with anxiety and mood disorders","volume":"39","author":"Rutter","year":"2017","journal-title":"J. Psychopathol. Behav. Assess."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0390","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1176\/ajp.151.12.1723","article-title":"Alcohol dependence and anxiety disorders: what is the relationship?","volume":"151","author":"Schuckit","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0395","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-0035-1547237","article-title":"Recent developments in pharmacotherapy of alcoholism","volume":"48","author":"Soyka","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0400","series-title":"Manual for the State-Trait Anxiety Inventory","author":"Spielberger","year":"1983"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0405","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0410","doi-asserted-by":"crossref","first-page":"121","DOI":"10.35946\/arcr.v39.2.03","article-title":"Functional and psychiatric correlates of comorbid post-traumatic stress disorder and alcohol use disorder","volume":"39","author":"Straus","year":"2018","journal-title":"Alcohol Res."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0415","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar)","volume":"84","author":"Sullivan","year":"1989","journal-title":"Br. J. Addict."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0420","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1472-8206.2006.00459.x","article-title":"Preclinical and clinical pharmacology of alcohol dependence","volume":"21","author":"Tambour","year":"2007","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0425","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","article-title":"Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010","volume":"382","author":"Whiteford","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0430","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.yebeh.2019.01.005","article-title":"Psychometric properties and diagnostic utility of the State-Trait Anxiety Inventory in epilepsy with and without comorbid anxiety disorder","volume":"92","author":"Wiglusz","year":"2019","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neubiorev.2020.12.030_bib0435","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."}],"container-title":["Neuroscience & Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763420307053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763420307053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T09:58:59Z","timestamp":1758967139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763420307053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":87,"alternative-id":["S0149763420307053"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2020.12.030","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2020.12.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}